

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE SIX MONTHS ENDED 30 JUNE 2024

On 11 July 2024, Dong-E-E-Jiao released its results estimate for the six months ended 30 June 2024.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 9.00% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.50% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 22.31% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 11 July 2024, Dong-E-E-Jiao released its results estimate for the six months ended 30 June 2024, in which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the six months ended 30 June 2024 is estimated to range from approximately RMB695 million to RMB760 million, representing an increase between approximately 31% and 43% (as compared to that of approximately RMB531.1136 million for the same period last year), net profit excluding non-recurring gain or loss is estimated to range from approximately RMB658 million to RMB723 million, representing an increase between approximately 34% and 48% (as compared to that of approximately RMB489.9443 million for the same period last year), and basic earnings per share is estimated to range from approximately RMB1.08 per share to approximately RMB1.18 per share (as compared to that of approximately RMB0.8247 per share for the same period last year) (the “**Dong-E-E-Jiao Results Estimate**”).

The main reasons for the change in results are set forth as follows:

1. Dong-E-E-Jiao focuses on the key theme of “growth and quality” and steadily advances its “1238” development strategy, and consistently implements the principles of “reshaping values, businesses, organisation and ethos.” It adheres to a consumer-centric approach, systematically builds a distinctive brand, integrates and upgrades brand rejuvenation, combines precise digital touchpoints with content dissemination, and fully empowers channel development. It firmly implements the “dual-driver” growth model of pharmaceuticals and health consumer products, with its growth of value chain led by E-Jiao block, the complete deployment of the comprehensive strategy of compound E-Jiao paste products, the significant results shown by the national brand expansion of Taohuaji E-Jiao cake, the gradual momentum gained by “Dong-E-E-Jiao Little Gold Bar” instant E-Jiao powder, and the new trend of men’s nourishment led by its “Royal Weichang 1619”, thereby driving steady and high-quality performance growth.
2. In the future, Dong-E-E-Jiao will further advance its “1238” development strategy with a comprehensive and systematic layout, actively explore new avenues for nourishment products, innovate the nourishment and health preservation sectors, continuously strengthen and expand the core E-Jiao business, vigorously develop “E-Jiao+” and “+E-Jiao”, firmly shoulder the responsibility of inheriting excellent traditional Chinese medicine culture and promoting the development of innovative traditional Chinese medicine industry. It will unleash new vitality through new qualitative productivity and strive to become the most trusted leader in nourishment and health for the public.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For the details of financial data, those to be disclosed in the interim report for the six months ended 30 June 2024 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational of financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Hong Kong, 12 July 2024

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.